How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure

Many patients with heart failure have an iron‐deficient state, which can limit erythropoiesis in erythroid precursors and ATP production in cardiomyocytes. Yet, treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors produces consistent increases in haemoglobin and haematocrit, even in pati...

Descripción completa

Detalles Bibliográficos
Autor principal: Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Sglt2 Inhibitors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100235/
https://www.ncbi.nlm.nih.gov/pubmed/36377108
http://dx.doi.org/10.1002/ejhf.2731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100235/
https://www.ncbi.nlm.nih.gov/pubmed/36377108
http://dx.doi.org/10.1002/ejhf.2731

Ejemplares similares